Adrenochrome Monosemicarbazone


Adrenochrome is indicated in control capillary bleeding, haemoptysis, epistemic, haematuria, retinal hemorrhage, secondary hemorrhage from wounds

Therapeutic Class

Anti-fibrinolytic drugs


Adrenochrome Monosemicarbazone is a haemostatic with a rapid onset of action. It contains a water soluble form of adrenochrome monosemicarbazone, a stable derivative of adrenochrome as the active substance. Adrenochrome is an oxidation product of adrenaline; it reduces normal and pathologic bleeding time by decreasing capillary permeability. It produces capillary haemostatis without exerting any of the adrenergic actions on respiration or cardiovascular system. Thus, despite its adrenaline like action on small blood vessels, does not give rise to the general systemic effects of sympathomimetic drugs.

Dosage & Administration

Oral (Adult)-
  • As a haemostatic: 10-30 mg tid.
Injection (Adult)-
  • As a haemostatic: 10 mg daily by SC/IM inj. Alternatively, 25-100 mg daily by IV Inj or drip infusion.
  • Pre-operative: 2-6 ml at suitable intervals.
  • Post-operative: 1-2 ml every 2 hrs.
  • Non-surgical: 2-4 ml tid.
Injection (Child <6 years): 1-2 ml tid.


No specific drug interaction has been demonstrated.


Should not be administered to patients with hypersensitivity

Side Effects

Allergic reactions may occur like dyspnoea, bronchospasm, skin reaction etc

Pregnancy & Lactation

Pregnancy Category-Not Classified. FDA has not yet classified the drug into a specified pregnancy category


Because of the content of diprophylline (90 mg/ml), the dosage to premature babies, infants and young children should not exceed 0.3 ml.